A methylation panel comprising ADHFE1, SDC2, and PPP2R5C correctly identified CRC with a sensitivity of 84.6% and specificity of 92.4% in stool samples, and it had a higher sensitivity than FIT alone in detecting advanced precancerous lesions. This evidence concerns the gene ADHFE1 and colorectal carcinoma.